$HURA
TuHURA Biosciences, Inc./NV Stock $hura

$hura Overview Financials Valuation SEC Filings Company Website

2022 Q2 Form 10-Q Financial Statement

#000095017022009809 Filed on May 13, 2022

Income Statement

Concept	2022 Q2	2022 Q1	2021 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.454M	$1.884M	$1.993M
YoY Change	-45.46%	-31.74%	-28.57%
% of Gross Profit
Research & Development	$4.004M	$3.474M	$3.902M
YoY Change	-0.67%	-9.6%	51.01%
% of Gross Profit
Depreciation & Amortization	$15.00K	$15.00K	$15.00K
YoY Change	25.0%	-25.0%
% of Gross Profit
Operating Expenses	$5.458M	$5.358M	$5.895M
YoY Change	-18.5%	-18.88%	9.61%
Operating Profit
YoY Change
Interest Expense	$12.00K	$2.000K	$2.000K
YoY Change	-134.29%	-71.43%	-75.0%
% of Operating Profit
Other Income/Expense, Net		$2.000K	$2.000K
YoY Change		-106.67%	-105.71%
Pretax Income	-$5.446M	-$5.356M	-$5.893M
YoY Change	-19.1%	-19.34%	8.93%
Income Tax
% Of Pretax Income
Net Earnings	-$5.446M	-$5.356M	-$5.893M
YoY Change	-19.1%	-19.28%	8.87%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.11	$0.12
Diluted Earnings Per Share	-$86.47K	-$109.0K	-$121.4K
COMMON SHARES
Basic Shares Outstanding	65.53M	49.13M	48.53M
Diluted Shares Outstanding

Balance Sheet

Concept	2022 Q2	2022 Q1	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.78M	$8.839M	$14.06M
YoY Change	11.8%	-43.77%	-18.04%
Cash & Equivalents	$11.78M	$8.839M	$14.06M
Short-Term Investments
Other Short-Term Assets	$1.478M	$1.254M	$934.0K
YoY Change	17.68%	45.81%	69.82%
Inventory
Prepaid Expenses	$1.478M	$1.254M
Receivables
Other Receivables
Total Short-Term Assets	$13.26M	$10.09M	$15.00M
YoY Change	12.42%	-39.15%	-15.35%
LONG-TERM ASSETS
Property, Plant & Equipment	$90.00K	$105.0K	$120.0K
YoY Change	-40.0%	-36.36%	-30.23%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$2.600M	$2.600M	$2.600M
YoY Change	62.5%	23.81%	0.0%
Total Long-Term Assets	$2.690M	$2.705M	$2.720M
YoY Change	53.71%	19.43%	-1.88%
TOTAL ASSETS
Total Short-Term Assets	$13.26M	$10.09M	$15.00M
Total Long-Term Assets	$2.690M	$2.705M	$2.720M
Total Assets	$15.95M	$12.80M	$17.72M
YoY Change	17.76%	-32.12%	-13.52%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.269M	$2.782M	$2.895M
YoY Change	47.32%	68.61%	46.95%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$3.990M	$3.240M	$3.438M
YoY Change	43.53%	27.91%	26.07%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$163.0K	$172.0K	$178.0K
YoY Change	-10.44%	-14.0%	-1.11%
Total Long-Term Liabilities	$163.0K	$172.0K	$178.0K
YoY Change	-10.44%	-14.0%	-1.11%
TOTAL LIABILITIES
Total Short-Term Liabilities	$3.990M	$3.240M	$3.438M
Total Long-Term Liabilities	$163.0K	$172.0K	$178.0K
Total Liabilities	$4.153M	$3.412M	$3.616M
YoY Change	40.21%	24.75%	24.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$136.4M	-$130.9M	-$125.6M
YoY Change	22.59%	25.28%	28.31%
Common Stock	$135.6M	$127.7M
YoY Change	26.88%	26.63%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.80M	$9.386M	$14.10M
YoY Change
Total Liabilities & Shareholders Equity	$15.95M	$12.80M	$17.72M
YoY Change	17.76%	-32.12%	-13.52%

Cashflow Statement

Concept	2022 Q2	2022 Q1	2021 Q4
OPERATING ACTIVITIES
Net Income	-$5.446M	-$5.356M	-$5.893M
YoY Change	-19.1%	-19.28%	8.87%
Depreciation, Depletion And Amortization	$15.00K	$15.00K	$15.00K
YoY Change	25.0%	-25.0%
Cash From Operating Activities	-$4.992M	-$5.223M	-$5.104M
YoY Change	6.44%	12.81%	-6.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	7.933M	-2.000K	-171.0K
YoY Change	-1722.29%	-100.06%	1610.0%
NET CHANGE
Cash From Operating Activities	-4.992M	-5.223M	-5.104M
Cash From Investing Activities	0.000	0.000	0.000
Cash From Financing Activities	7.933M	-2.000K	-171.0K
Net Change In Cash	2.941M	-5.225M	-5.275M
YoY Change	-156.83%	260.34%	-3.03%
FREE CASH FLOW
Cash From Operating Activities	-$4.992M	-$5.223M	-$5.104M
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$4.992M	-$5.223M
YoY Change	6.39%	13.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001498382
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37823
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q2	us-gaap	Assets Current AssetsCurrent	11793000
CY2022Q1	ktra	Clinical Trial Deposit Non Current ClinicalTrialDepositNonCurrent	2600000
CY2021Q2	ktra	Clinical Trial Deposit Non Current ClinicalTrialDepositNonCurrent	1600000
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	105000
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	150000
CY2022Q1	us-gaap	Assets Assets	12798000
CY2021Q2	us-gaap	Assets Assets	13543000
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	65532826
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8839000
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	10537000
CY2022Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1254000
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	756000
CY2021Q2	ktra	Clinical Trial Deposit Current ClinicalTrialDepositCurrent	500000
CY2022Q1	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2782000
CY2021Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2219000
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	458000
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	561000
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	3240000
CY2022Q1	us-gaap	Assets Current AssetsCurrent	10093000
	dei	Entity Registrant Name EntityRegistrantName	Kintara Therapeutics, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	99-0360497
	dei	Entity Address Address Line1 EntityAddressAddressLine1	9920 Pacific Heights Blvd
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 150
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92121
	dei	City Area Code CityAreaCode	858
	dei	Local Phone Number LocalPhoneNumber	350-4364
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	KTRA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	2780000
CY2022Q1	ktra	Milestone Payment Liability MilestonePaymentLiability	172000
CY2021Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	182000
CY2022Q1	us-gaap	Liabilities Liabilities	3412000
CY2021Q2	us-gaap	Liabilities Liabilities	2962000
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7091000
	ktra	Merger Costs MergerCosts	500000
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	175000000
CY2022Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	49306000
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32740000
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	49000
CY2021Q2	us-gaap	Common Stock Value CommonStockValue	33000
CY2022Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	127670000
CY2021Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	106821000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130908000
CY2021Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-111225000
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000
CY2021Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	21000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9386000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	10581000
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12798000
CY2021Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13543000
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3474000
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3843000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11169000
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7784000
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1884000
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2762000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6055000
	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	5358000
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	6605000
	us-gaap	Operating Expenses OperatingExpenses	17224000
	us-gaap	Operating Expenses OperatingExpenses	31469000
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1000
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	6000
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3000
CY2021Q1	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	23000
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	74000
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1000
CY2021Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-6000
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	3000
	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-20000
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2000
CY2021Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-30000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-97000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5356000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6635000
	us-gaap	Net Income Loss NetIncomeLoss	-17215000
	us-gaap	Net Income Loss NetIncomeLoss	-31566000
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-5356000
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-6635000
	us-gaap	Net Income Loss NetIncomeLoss	-17215000
	us-gaap	Net Income Loss NetIncomeLoss	-31566000
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	3181000
CY2022Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2000
CY2021Q1	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	2000
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	6000
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	6000
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5358000
CY2021Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6643000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-19683000
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-34768000
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.47
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	49128000
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	29273000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43942000
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	23701000
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	10581000
CY2021Q3	ktra	Issuance Of Shares And Warrants Net Of Issue Cost IssuanceOfSharesAndWarrantsNetOfIssueCost	13634000
CY2021Q3	ktra	Exercise Of2020 Investor Warrants For Cash ExerciseOf2020InvestorWarrantsForCash	69000
CY2021Q3	ktra	Exercise Of Pre Funded Warrants For Cash ExerciseOfPreFundedWarrantsForCash	5000
CY2021Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	31000
CY2021Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	811000
CY2021Q3	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2021Q3	us-gaap	Profit Loss ProfitLoss	-5966000
CY2021Q3	us-gaap	Stockholders Equity StockholdersEquity	19163000
CY2021Q4	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	4000
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	830000
CY2021Q4	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2021Q4	us-gaap	Profit Loss ProfitLoss	-5893000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	14102000
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	642000
CY2022Q1	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-5356000
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	9386000
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	263000
CY2020Q3	ktra	Adgero Merger Value AdgeroMergerValue	16725000
CY2020Q3	ktra	Issuance Of Series C Preferred Stock IssuanceOfSeriesCPreferredStock	25028000
CY2020Q3	ktra	Series C Preferred Stock Issue Costs SeriesCPreferredStockIssueCosts	-3386000
	ktra	Proceeds From Issuance Of Shares And Warrants ProceedsFromIssuanceOfSharesAndWarrants	21598000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	74000
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	4399000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	42000
CY2020Q3	ktra	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	994000
CY2020Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	45000
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	405000
CY2020Q3	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2020Q3	us-gaap	Profit Loss ProfitLoss	-19518000
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	20554000
CY2020Q4	ktra	Series C Preferred Stock Issue Costs SeriesCPreferredStockIssueCosts	-69000
CY2020Q4	ktra	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	186000
CY2020Q4	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	183000
CY2020Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000
CY2020Q4	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2125000
CY2020Q4	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2020Q4	us-gaap	Profit Loss ProfitLoss	-5413000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	17585000
CY2021Q1	ktra	Exercise Of Warrants For Cash ExerciseOfWarrantsForCash	3219000
CY2021Q1	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	210000
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	22000
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1719000
CY2021Q1	ktra	Series Preferred Stock Dividends SeriesPreferredStockDividends	-2000
CY2021Q1	us-gaap	Profit Loss ProfitLoss	-6635000
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	16118000
	us-gaap	Profit Loss ProfitLoss	-17215000
	us-gaap	Profit Loss ProfitLoss	-31566000
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2000
	us-gaap	Depreciation Depreciation	45000
	us-gaap	Depreciation Depreciation	15000
	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
	ktra	Gain Loss From Change In Fair Value Of Milestone Liability GainLossFromChangeInFairValueOfMilestoneLiability	10000
	ktra	Gain Loss From Change In Fair Value Of Milestone Liability GainLossFromChangeInFairValueOfMilestoneLiability	-14000
	us-gaap	Interest Expense InterestExpense	23000
	ktra	Amortization Of Deferred Loan Costs AmortizationOfDeferredLoanCosts	74000
	ktra	Increase Decrease In Fair Value Of Warrants Issued For Services IncreaseDecreaseInFairValueOfWarrantsIssuedForServices	35000
	ktra	Increase Decrease In Fair Value Of Warrants Issued For Services IncreaseDecreaseInFairValueOfWarrantsIssuedForServices	438000
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2283000
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	4248000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	998000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2594000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	563000
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-640000
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-103000
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-279000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15400000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14171000
	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	969000
	us-gaap	Payments To Acquire Machinery And Equipment PaymentsToAcquireMachineryAndEquipment	8000
	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	3000
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	964000
	ktra	Proceeds From Issuance Of Shares And Warrants ProceedsFromIssuanceOfSharesAndWarrants	13634000
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-130908000
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	8839000
	ktra	Substantial Doubt About Companys Ability To Continues Going Concern Period SubstantialDoubtAboutCompanysAbilityToContinuesGoingConcernPeriod	P1Y
	us-gaap	Proceeds From Construction Loans Payable ProceedsFromConstructionLoansPayable	500000
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	6000
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	6000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	13702000
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	26533000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1698000
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	13326000
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10537000
CY2020Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2392000
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	8839000
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15718000
	us-gaap	Nature Of Operations NatureOfOperations	<p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1 Nature of operations, corporate history, and going concern and management plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Nature of operations</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kintara Therapeutics, Inc. (the “Company”) is a clinical-stage drug development company with a focus on the development of novel cancer therapies for patients with unmet medical needs. The Company is developing two late-stage, Phase 3-ready therapeutics - VAL-083 for glioblastoma multiforme and REM-001 for cutaneous metastatic breast cancer. In order to accelerate the Company’s development timelines, it leverages existing preclinical and clinical data from a wide range of sources. The Company may seek marketing partnerships in order to potentially offset clinical costs and to generate future royalty revenue from approved indications of its product candidates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">On June 9, 2020, the Company entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”), by and among Adgero Acquisition Corp., the Company’s wholly-owned subsidiary incorporated in the State of Delaware (“Merger Sub”), and Adgero Biopharmaceuticals Holdings, Inc., a Delaware corporation (“Adgero”). On August 19, 2020, upon the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and into Adgero (the “Merger”), the separate corporate existence of Merger Sub ceased and Adgero continued its existence under Delaware law as the surviving corporation in the Merger and became a direct, wholly-owned subsidiary of the Company. As a result of the Merger, each issued and outstanding share of Adgero common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">0.0001</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> per share (the “Adgero Common Stock”) (other than treasury shares held by Adgero), was converted automatically into </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">1.5740 shares</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> (the “Exchange Ratio”) of the Company’s common stock per share of Adgero Common Stock, and cash in lieu of any fractional shares. Also, each outstanding warrant to purchase Adgero Common Stock was converted into a warrant exercisable for that number of shares of the Company’s common stock equal to the product of (x) the aggregate number of shares of Adgero Common Stock for which such warrant was exercisable and (y) the Exchange Ratio.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Following the completion of the Merger, the Company changed its name from DelMar Pharmaceuticals, Inc. to Kintara Therapeutics, Inc. and began trading on Nasdaq under the symbol “KTRA”.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Corporate history</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company is a Nevada corporation formed on June 24, 2009 under the name Berry Only, Inc. On January 25, 2013, the Company entered into and closed an exchange agreement (the “Exchange Agreement”), with Del Mar Pharmaceuticals (BC) Ltd. (“Del Mar (BC)”), 0959454 B.C. Ltd. (“Callco”), and 0959456 B.C. Ltd. (“Exchangeco”) and the security holders of Del Mar (BC). Upon completion of the Exchange Agreement, Del Mar (BC) became a wholly-owned subsidiary of the Company (the “Reverse Acquisition”).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Kintara Therapeutics, Inc. is the parent company of Del Mar (BC), a British Columbia, Canada corporation and Adgero, a Delaware corporation, which are clinical-stage companies with a focus on the development of drugs for the treatment of cancer. The Company is also the parent company to Callco and Exchangeco which are British Columbia, Canada corporations. Callco and Exchangeco were formed to facilitate the Reverse Acquisition. In connection with the Merger, the Company also became the parent company of Adgero Biopharmaceuticals, Inc. (“Adgero Bio”), formerly a wholly-owned subsidiary of Adgero.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">References to the Company refer to the Company and its wholly-owned subsidiaries.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Going concern and management plans</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.0110416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">These condensed consolidated interim financial statements have been prepared on a going concern basis, which assumes that the Company will continue its operations for the foreseeable future and contemplates the realization of assets and the settlement of liabilities in the normal course of business.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">For the nine months ended March 31, 2022, the Company reported a loss of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">17,215</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and a negative cash flow from operations of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">15,400</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">. The Company had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">130,908</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> and had cash and cash equivalents of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">8,839</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> as of March 31, 2022. The Company is in the clinical stage and has not generated any revenues to date. The Company does not have the prospect of achieving revenues until such time that its product candidates are commercialized, or partnered, which may not ever occur. On April 14, 2022, the Company completed a registered direct financing for net proceeds of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">7.9</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> million. Even with the proceeds from this financing, the Company will require additional funding to maintain its clinical trials, research and development projects, and for general operations. These circumstances indicate substantial doubt exists about the Company’s ability to continue as a going concern within </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">one year</span></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;"> from the date of filing of these condensed consolidated interim financial statements.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Consequently, management is pursuing various financing alternatives to fund the Company’s operations so it can continue as a going concern. However, the coronavirus (“COVID-19”) pandemic has created significant economic uncertainty and volatility in the credit and capital markets. Management plans to continue to pursue opportunities to secure the necessary financing through the issue of new equity, debt, and/or the entering into of strategic partnership arrangements but the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">ultimate impact of the COVID-19 pandemic on the Company’s ability to raise additional capital is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak and any new information which may emerge concerning the severity of the COVID-19 pandemic. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The Company may not be able to raise sufficient additional capital and may tailor its drug candidate development programs based on the amount of funding the Company is able to raise in the future. Nevertheless, there is no assurance that these initiatives will be successful.</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">These condensed consolidated financial statements do not give effect to any adjustments to the amounts and classification of assets and liabilities that may be necessary should the Company be unable to continue as a going concern. Such adjustments could be material.</span></p>
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Common Stock Conversion Basis CommonStockConversionBasis	1.5740 shares
	us-gaap	Net Income Loss NetIncomeLoss	-17215000
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15400000
	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">Use of estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions about future events that affect the reported amounts of assets, liabilities, expenses, contingent assets, and contingent liabilities as at the end of, or during, the reporting period. Actual results could significantly differ from those estimates. Significant areas requiring management to make estimates include the valuation of equity instruments issued for services and clinical trial accruals. Further details of the nature of these assumptions and conditions may be found in the relevant notes to these condensed consolidated interim financial statements.</span></p>
CY2022Q1	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	1840000
CY2021Q1	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	1708000
	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	5770000
	ktra	Patient Enrollment Milestones Payments PatientEnrollmentMilestonesPayments	2958000
	ktra	In Progress Research And Development Expense InProgressResearchAndDevelopmentExpense	16094000
	ktra	Property Equipment And Intangibles Estimated Useful Life PropertyEquipmentAndIntangiblesEstimatedUsefulLife	P3Y
	us-gaap	Legal Fees LegalFees	1554000
	us-gaap	Professional Fees ProfessionalFees	500000
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	300000
CY2022Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	240000
	us-gaap	Payments To Employees PaymentsToEmployees	60000
CY2021Q2	ktra	Milestone Payment Liability MilestonePaymentLiability	182000
	ktra	Milestone Payment Liability Change In Fair Value Estimate MilestonePaymentLiabilityChangeInFairValueEstimate	-10000
CY2022Q1	ktra	Milestone Payment Liability MilestonePaymentLiability	172000
	ktra	Deposits Payments DepositsPayments	2600000
CY2022Q1	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	458000
CY2021Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	561000
	ktra	Underwritten Public Offerings Description UnderwrittenPublicOfferingsDescription	the Company closed on the sale of (i) 7,200 shares of its common stock, par value $0.001 per share, (ii) pre-funded warrants (“PFW”) to purchase an aggregate of 4,800 shares of common stock and (iii) common warrants to purchase an aggregate of 12,000 shares of common stock (“2022 Investor Warrants”) in the Company’s registered direct offering (the “September Offering”). Each share of common stock, or PFW as applicable, was sold together with a 2022 Investor Warrant to purchase one share of common stock at a combined effective price of $1.25 per share of common stock and accompanying 2022 Investor Warrant. The 2022 Investor Warrants have been valued at $7,023 and have been treated as equity. They have been valued using a Black-Scholes valuation with a risk-free rate of 0.55%, a contractual term of 3.5 years, a volatility of 116.7%, and a dividend rate of 0%.
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9846000
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4060000
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	642000
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1718000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2283000
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4248000
CY2021Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	3860000
CY2021Q2	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice	1.60
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3964000
	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsGrantedWeightedAverageExercisePrice	0.99
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	1556000
	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsVestedWeightedAverageExercisePrice	1.55
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	482000
	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsForfeitedWeightedAverageExercisePrice	1.64
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	5786000
CY2022Q1	ktra	Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionsUnvestedWeightedAverageExercisePrice	1.19
	ktra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P9Y2M1D
	ktra	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageRemainingContractualTerm	P9Y4M20D
	us-gaap	Dividends Preferred Stock Stock DividendsPreferredStockStock	3181000
	ktra	Non Cash Issue Costs NonCashIssueCosts	333000
	ktra	Non Cash Issue Costs NonCashIssueCosts	3287000

Files In Submission

Name	View Source	Status
0000950170-22-009809-index-headers.html	Edgar Link	pending
0000950170-22-009809-index.html	Edgar Link	pending
0000950170-22-009809.txt	Edgar Link	pending
0000950170-22-009809-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
img138739316_0.jpg	Edgar Link	pending
img138739316_1.jpg	Edgar Link	pending
ktra-20220331.htm	Edgar Link	pending
ktra-20220331.xsd	Edgar Link	pending
ktra-20220331_cal.xml	Edgar Link	unprocessable
ktra-20220331_def.xml	Edgar Link	unprocessable
ktra-20220331_htm.xml	Edgar Link	completed
ktra-20220331_lab.xml	Edgar Link	unprocessable
ktra-20220331_pre.xml	Edgar Link	unprocessable
ktra-ex31_1.htm	Edgar Link	pending
ktra-ex31_2.htm	Edgar Link	pending
ktra-ex32_1.htm	Edgar Link	pending
ktra-ex32_2.htm	Edgar Link	pending
ktra-ex3_1.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HURA
TuHURA Biosciences, Inc./NV Stock $hura

2022 Q2 Form 10-Q Financial Statement

#000095017022009809 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HURA TuHURA Biosciences, Inc./NV Stock $hura

2022 Q2 Form 10-Q Financial Statement

#000095017022009809 Filed on May 13, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HURA
TuHURA Biosciences, Inc./NV Stock $hura